Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022
For the year, preliminary unaudited annual 2022 revenue is expected to be approximately 128.2 million, representing a decline of 2% from 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.045 USD | -5.98% |
|
+57.31% | -79.15% |
1st Jan change | Capi. | |
---|---|---|
-79.15% | 592M | |
+4.74% | 212B | |
+8.73% | 187B | |
+26.75% | 155B | |
+33.92% | 115B | |
+2.17% | 65.5B | |
+14.12% | 52.87B | |
-3.30% | 45.25B | |
-3.30% | 39.7B | |
+6.44% | 37.72B |